Impact of proton pump inhibitor use on magnesium homoeostasis: A cross-sectional study in a tertiary emergency department

International Journal of Clinical Practice

Volumn 68, Issue 11, 2014, Pages 1352-1357

  Lindner, G ^a   Funk, G C ^b   Leichtle, A B ^c   Fiedler, G M ^c   Schwarz, C ^d   Eleftheriadis, T ^e   Pasch, A ^a   Mohaupt, M G ^a   Exadaktylos, A K ^a   Arampatzis, Spyridon ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b OTTO WAGNER HOSPITAL   (Austria)

^c UNIVERSITY OF BERN   (Switzerland)

^d Department of Nephrology LKH   (Austria)

^e UNIVERSITY OF THESSALY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CHLORIDE; DIURETIC AGENT; MAGNESIUM; PHOSPHATE; POTASSIUM; PROTON PUMP INHIBITOR; SODIUM;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CHLORIDE BLOOD LEVEL; COMORBIDITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE PREDISPOSITION; ELECTROLYTE BLOOD LEVEL; EMERGENCY WARD; FEMALE; HUMAN; HYPOMAGNESEMIA; KIDNEY FUNCTION; LENGTH OF STAY; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINERAL METABOLISM; MORTALITY; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; PREVALENCE; SODIUM BLOOD LEVEL; TERTIARY CARE CENTER; AGED; BLOOD; COHORT ANALYSIS; DRUG EFFECTS; EMERGENCY HEALTH SERVICE; HOMEOSTASIS;

ADULT; AGED; COHORT STUDIES; CROSS-SECTIONAL STUDIES; EMERGENCY SERVICE, HOSPITAL; FEMALE; HOMEOSTASIS; HUMANS; MAGNESIUM; MALE; MIDDLE AGED; PREVALENCE; PROTON PUMP INHIBITORS;

EID: 84916624920     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12469     Document Type: Article

References (34)

1. Katz MH,. Failing the acid test: benefits of proton pump inhibitors may not justify the risks for many users. Arch Intern Med 2010; 170: 747-8.
2. Forgacs I, Loganayagam A,. Overprescribing proton pump inhibitors. BMJ 2008; 336: 2-3.
3. Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008; 83: 251-9.
4. Wise MP, Saayman AG, Frost PJ,. Acid-suppressive medication and hospital-acquired pneumonia. JAMA 2009; 302: 1416; author reply -7.
5. Linsky A, Gupta K, Lawler EV, et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 2010; 170: 772-8.
6. Epstein M, McGrath S, Law F,. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 2006; 355: 1834-6.
7. Metz DC, Sostek MB, Ruszniewski P, et al. Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol 2007; 102: 2648-54.
8. Shabajee N, Lamb EJ, Sturgess I, Sumathipala RW, Omeprazole and refractory hypomagnesaemia. BMJ 2008; 337: a425.
9. Cundy T, Dissanayake A,. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf) 2008; 69: 338-41.
10. Francois M, Levy-Bohbot N, Caron J, Durlach V,. Chronic use of proton-pump inhibitors associated with giardiasis: a rare cause of hypomagnesemic hypoparathyroidism? Ann Endocrinol 2008; 69: 446-8.
11. Hmu C, Moulik P, Macleod A,. Severe hypomagnesaemia due to lansoprazole. BMJ Case Rep 2009; http://dx.doi.org/10.1136%2Fbcr.07.2009.2098 (accessed 20 May 2014).
12. Broeren MA, Geerdink EA, Vader HL, van den Wall Bake AW,. Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med 2009; 151: 755-6.
13. Hoorn EJ, van der Hoek J, de Man RA, et al. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis 2010; 56: 112-6.
14. Regolisti G, Cabassi A, Parenti E, et al. Severe hypomagnesemia during long-term treatment with a proton pump inhibitor. Am J Kidney Dis 2010; 56: 168-74.
15. Ayuk J, Gittoes NJ,. How should hypomagnesaemia be investigated and treated? Clin Endocrinol (Oxf) 2011; 75: 743-6.
16. Furlanetto TW, Faulhaber GA,. Hypomagnesemia and proton pump inhibitors: below the tip of the iceberg. Arch Intern Med 2011; 171: 1391-2.
17. Negri AL, Valle EE,. Hypomagnesaemia/hypokalemia associated with the use of esomeprazole. Current Drug Safety 2011; 6: 204-6.
18. Mackay JD, Bladon PT,. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. QJM 2010; 103: 387-95.
19. Quasdorff M, Mertens J, Dinter J, Steffen HM,. Recurrent hypomagnesemia with proton-pump inhibitor rechallenge. Ann Intern Med 2011; 155: 405-7.
20. US Department of Health and Human Services F DSC. Proton pump inhibitor drugs (PPIs): drug safety communication-low magnesium levels can be associated with long-term use, 2011. http://www.fda.gov/Drugs/DrugSafety/ucm245011.htm (accessed 25 February 2013)
21. Danziger J, William JH, Scott DJ, et al. Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int 2013; 83: 692-9.
22. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70.
23. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
24. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130-9.
25. Schlingmann KP, Weber S, Peters M, et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat Genet 2002; 31: 166-70.
26. Hou J, Renigunta A, Konrad M, et al. Claudin-16 and claudin-19 interact and form a cation-selective tight junction complex. J Clin Invest 2008; 118: 619-28.
27. Bai JP, Hausman E, Lionberger R, Zhang X,. Modeling and simulation of the effect of proton pump inhibitors on magnesium homeostasis. 1. Oral absorption of magnesium. Mol Pharm 2012; 9: 3495-505.
28. Lameris AL, Hess MW, van Kruijsbergen I, et al. Omeprazole enhances the colonic expression of the Mg(2+) transporter TRPM6. Pflugers Arch 2013; 465: 1613-20.
29. Arampatzis S, Funk GC, Leichtle AB, et al. Impact of diuretic therapy-associated electrolyte disorders present on admission to the emergency department: a cross-sectional analysis. BMC Med 2013; 11: 83.
30. Arampatzis S, Gaetcke LM, Funk GC, et al. Diuretic-induced hyponatremia and osteoporotic fractures in patients admitted to the emergency department. Maturitas 2013; 75: 81-6.
31. Moe SM,. Disorders involving calcium, phosphorus, and magnesium. Prim Care 2008; 35: 215-37, v-vi.
32. Dai LJ, Friedman PA, Quamme GA,. Cellular mechanisms of chlorothiazide and cellular potassium depletion on Mg2+ uptake in mouse distal convoluted tubule cells. Kidney Int 1997; 51: 1008-17.
33. Leone N, Courbon D, Ducimetiere P, Zureik M,. Zinc, copper, and magnesium and risks for all-cause, cancer, and cardiovascular mortality. Epidemiology 2006; 17: 308-14.
34. Tsuji H, Venditti FJ Jr, Evans JC, et al. The associations of levels of serum potassium and magnesium with ventricular premature complexes (the Framingham Heart Study). Am J Cardiol 1994; 74: 232-5.